Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kartik Sehgal

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2025
Personalized Thyroidology: Molecular Rewiring of Thyroid Nodule ManagementKartik Sehgal
The Journal of Clinical Investigation|January 4, 2021
Targeting the mutant p53 secretomeKartik Sehgal, David A Barbie
Cancer Research|December 4, 2019
Clonal Selection Drives NF-κB Activation in Recurrent Nasopharyngeal CarcinomaKartik Sehgal, David A Barbie
World Journal of Pediatric Surgery|December 7, 2022
Size of atrial septal defect after balloon atrial septostomy does not correlate with immediate improvement in oxygenationKartik Sehgal, Kunal Sehgal, Suraj Varma
Frontiers in Oncology|July 28, 2020
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?Kartik Sehgal, Daniel B Costa, Deepa Rangachari
Immunology Letters|July 30, 2014
Targeting human dendritic cells in situ to improve vaccinesKartik Sehgal, Kavita M Dhodapkar, Madhav V Dhodapkar
Journal of Paediatrics and Child Health|April 1, 2020
Diuretic use in infants with developing or established chronic lung disease: A practice looking for evidenceCatherine Tan, Kartik Sehgal, Kunal Sehgal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 2014
Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalkKartik Sehgal, Ragy Ragheb, Tarek M Fahmy, et al.
The Oncologist|September 24, 2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR MutationsKartik Sehgal, Deepa Rangachari, Paul A VanderLaan, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Kartik Sehgal, Andreas Varkaris, Hollis Viray, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2025
Personalized Thyroidology: Molecular Rewiring of Thyroid Nodule ManagementKartik Sehgal
The Journal of Clinical Investigation|January 4, 2021
Targeting the mutant p53 secretomeKartik Sehgal, David A Barbie
Cancer Research|December 4, 2019
Clonal Selection Drives NF-κB Activation in Recurrent Nasopharyngeal CarcinomaKartik Sehgal, David A Barbie
World Journal of Pediatric Surgery|December 7, 2022
Size of atrial septal defect after balloon atrial septostomy does not correlate with immediate improvement in oxygenationKartik Sehgal, Kunal Sehgal, Suraj Varma
Frontiers in Oncology|July 28, 2020
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?Kartik Sehgal, Daniel B Costa, Deepa Rangachari
Immunology Letters|July 30, 2014
Targeting human dendritic cells in situ to improve vaccinesKartik Sehgal, Kavita M Dhodapkar, Madhav V Dhodapkar
Journal of Paediatrics and Child Health|April 1, 2020
Diuretic use in infants with developing or established chronic lung disease: A practice looking for evidenceCatherine Tan, Kartik Sehgal, Kunal Sehgal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 2014
Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalkKartik Sehgal, Ragy Ragheb, Tarek M Fahmy, et al.
The Oncologist|September 24, 2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR MutationsKartik Sehgal, Deepa Rangachari, Paul A VanderLaan, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Kartik Sehgal, Andreas Varkaris, Hollis Viray, et al.
Pageof 5